Premium
A subset of functional effector‐memory CD8 + T lymphocytes in human immunodeficiency virus‐infected patients
Author(s) -
Decrion AnneZélie,
Varin Audrey,
Drobacheff Christine,
Estavoyer JeanMarie,
Herbein Georges
Publication year - 2007
Publication title -
immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.297
H-Index - 133
eISSN - 1365-2567
pISSN - 0019-2805
DOI - 10.1111/j.1365-2567.2007.02589.x
Subject(s) - cd28 , cytotoxic t cell , biology , cd8 , antigen , immunology , interleukin 21 , immune system , virology , t lymphocyte , microbiology and biotechnology , biochemistry , in vitro
Summary CD8 + T cells provide protective immune responses via both cytolytic and non‐cytolytic mechanisms in subjects infected with human immunodeficiency virus (HIV). In the present study, we investigated the CD28 expression of CD8 + T cells present in the peripheral blood lymphocyte subset isolated from chronically HIV‐infected subjects. Using flow cytometric analysis, a continuous spectrum of CD28 intensity ranging from negative to high, which could be separated into CD28‐negative, intermediate (int) and high, was seen for CD8 + T cells. Our study focused mostly on the CD28 int CD8 + T cells. The CD28 int CD8 + T cells are CD57 – CD27 + CD45RO + CD45RA – CCR7 low CD62L int . The proliferative capacity of CD28 int CD8 + T cells was intermediate between those of CD28 – CD8 + T cells and CD28 high CD8 + T cells. The CD28 int CD8 + T cells are specific for HIV, cytomegalovirus (CMV) and Epstein–Barr virus (EBV) antigens as measured by human leucocyte antigen pentamer binding and produce both intracellular interferon‐γ and tumour necrosis factor‐α in response to their cognate viral peptides. The CD28 int CD8 + T cells have HIV‐specific, CMV‐specific and EBV‐specific cytotoxic activity in response to their cognate viral peptides. These findings indicate that a subset of functional effector‐memory CD8 + T cells specific for HIV, CMV and EBV antigens may contribute to an efficient immune response in HIV‐infected subjects.